TREATMENT OF CANCER WITH ALK1 ANTAGONISTS

摘要

Methods for evaluating responsiveness of a subject having cancer to treatment with an activin receptor-like kinase 1 (ALKl) antagonist are provided. Methods for selecting a subject for treatment with an ALKl antagonist based on the subject being identified as responsive to such treatment are also provided. Some of the diagnostic methods provided herein are based on detecting an ALKl agonist, e.g., an ALKl ligand such as BMP9 or BMP10, in a sample obtained from the subject. Diagnostic reagents and kits for determining whether a subject is responsive to treatment with an ALKl antagonist are also provided.